Pan Pi3k Inhibitors - Catalysis

Relevant Publications

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

Issue Release: 2025

Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes.

Issue Release: 2025

The Brain-Penetrant Pan ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases.

Issue Release: 2025

N-(5-(2-morpholino-4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)acylamides as novel multi-PI3K/DNA-PK/P-gp inhibitors for efficient chemosensitization and MDR alleviation.

Issue Release: 2025

Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With Mutations and Overcoming Strategies.

Issue Release: 2025

Integrated analysis of proteome and transcriptome profiling reveals pan-cancer-associated pathways and molecular biomarkers.

Issue Release: 2025

Impregnation of mesenchymal stem cell conditioned media with wortmannin enhanced its antiproliferative effect in breast cancer cells via PI3K/Akt/mTOR pathway.

Issue Release: 2025

Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia.

Issue Release: 2025

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma.

Issue Release: 2025

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence.

Issue Release: 2024

Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models.

Issue Release: 2024

Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor.

Issue Release: 2024

Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies.

Issue Release: 2024

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.

Issue Release: 2024

Inhibition of PI3K/AKT signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.

Issue Release: 2024

Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.

Issue Release: 2024

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.

Issue Release: 2024

The simultaneous use of CRISPR/Cas9 to knock out the PI3Kca gene with radiation to enhance radiosensitivity and inhibit tumor growth in breast cancer.

Issue Release: 2024

Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight.

Issue Release: 2024

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer.

Issue Release: 2024

How Can the Efficiency of Sieving Catalysts be Improved?

What are the Benefits of Innography for Researchers and Industry?

How Can a Consultant Help with Catalyst Selection?

What Are Some Recent Advances in Solid State NMR for Catalysis?

What are the challenges associated with cooling systems in catalysis?

How Can This Knowledge be Applied?

What are Rings in Catalysis?

How Does Catalysis Play a Role in Personalized Medicine?

What is a Liquid Medium in Catalysis?

What is Ultraviolet Radiation?

Pan Pi3k Inhibitors - Catalysis

Relevant Publications

Partnered Content Networks

Relevant Topics